Five things for pharma marketers to know: Thursday, October 20, 2016

 

1. Chicago plans to require all pharmaceutical sales reps to carry a special license with the aim of stemming opioid addiction. The license requires sales rep to track the doctors and other healthcare providers they've been in contact with and provide that information if requested by the city. (Chicago Tribune)

2. Nine of the 20 largest pharmaceutical companies by revenue now have corporate accounts on Instagram. GlaxoSmithKline is the most recent company to join the image-focused social network, saying it wants to use the account to “explore what's behind the science and discover some of the latest healthcare innovations.” (PMLiVE)

3. Eli Lilly received accelerated approval from the FDA for its experimental soft tissue sarcoma drug, olaratumab, after positives results from a Phase-II trial. The drug is expected to be used as a first-line treatment for this form of cancer. (Endpoints)

4. An FDA advisory committee voted 14-4 in favor of approving Allergan's nighttime urination nasal spray, SER120. The agency is not required to follow the agency's recommendations, but often does. (PharmaTimes)

5. ICYMI: Crispr Therapeutics did not hit its target for its initial public offering, suggesting that investor excitement has diminished for the company's gene-editing technology. The biotech raised $56 million Tuesday. (Boston Globe)